Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

The Real Life Topical Field Treatment of Actinic Keratosis Study

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Imiquimod
Drug: 5-fluorouracil
Drug: Ingenol mebutate
Drug: Diclofenac

First Posted Date: 2015-02-12

Last Posted Date: 2019-12-13

Lead Sponsor: LEO Pharma

Target Recruit Count: 1168

Registration Number: NCT02362152

Locations: 🇳🇱
Lievensberg Ziekenhuis, Bergen op Zoom, Netherlands

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Phase 3

Completed

Conditions: Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-FU
Biological: Cetuximab

First Posted Date: 2015-02-06

Last Posted Date: 2024-06-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 882

Registration Number: NCT02358031

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Phase 1

Withdrawn

Conditions: Stage IIIA Esophageal Cancer
Stage IIIA Gastric Cancer
Stage IIIB Esophageal Cancer
Stage IIIB Gastric Cancer
Adenocarcinoma of the Esophagus
Intestinal Adenocarcinoma of the Stomach
Adenocarcinoma of the Gastroesophageal Junction
Mixed Adenocarcinoma of the Stomach
Stage IIIC Esophageal Cancer
Stage IIIC Gastric Cancer

Interventions: Drug: c-Met inhibitor AMG 337
Other: placebo
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2015-01-26

Last Posted Date: 2023-05-25

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT02344810

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study

Phase 2

Terminated

Conditions: Pancreatic Adenocarcinoma
Stage IA Pancreatic Cancer
Poorly Differentiated Malignant Neoplasm
Stage IIB Pancreatic Cancer
Stage III Pancreatic Cancer
Undifferentiated Pancreatic Carcinoma
Resectable Pancreatic Cancer
Stage IB Pancreatic Cancer
Stage IIA Pancreatic Cancer

Interventions: Drug: Irinotecan Hydrochloride
Drug: Oxaliplatin
Drug: Leucovorin Calcium
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-01-26

Last Posted Date: 2018-07-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT02345460

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis

Phase 2

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2015-01-26

Last Posted Date: 2017-08-24

Lead Sponsor: Western Regional Medical Center

Registration Number: NCT02345746

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Phase 2

Completed

Conditions: Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Biological: pembrolizumab
Drug: cisplatin
Drug: 5-FU
Drug: capecitabine

First Posted Date: 2015-01-09

Last Posted Date: 2022-08-08

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 318

Registration Number: NCT02335411

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of Unknown Primary
Adult Cholangiocarcinoma
Gallbladder Carcinoma
Malignant Gastrointestinal Neoplasm
Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Gastric Adenocarcinoma
Stage III Ampulla of Vater Cancer
Stage III Pancreatic Cancer
Stage IIIA Gallbladder Cancer

Interventions: Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Drug: Leucovorin Calcium
Drug: Irinotecan Hydrochloride
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-01-07

Last Posted Date: 2023-05-31

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT02333188

Locations: 🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸
Virginia Mason, Seattle, Washington, United States

and more 5 locations

Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: fluorouracil
Drug: Cisplatin
Radiation: Intensity-modulated radiation therapy

First Posted Date: 2014-12-25

Last Posted Date: 2015-11-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 46

Registration Number: NCT02325986

Locations: 🇨🇳
SYSU Cancer Center, Guangzhou, Guangdong, China

Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors

Phase 1

Completed

Conditions: Malignant Digestive System Neoplasm

Interventions: Drug: Alisertib
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin

First Posted Date: 2014-12-18

Last Posted Date: 2018-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT02319018

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States

and more 2 locations

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Phase 3

Completed

Conditions: Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma

Interventions: Drug: Ramucirumab
Drug: Capecitabine
Drug: Placebo
Drug: Cisplatin
Drug: Fluorouracil

First Posted Date: 2014-12-10

Last Posted Date: 2021-08-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 645

Registration Number: NCT02314117

Locations: 🇺🇸
UT Southwestern Med Ctr, Dallas, Texas, United States
🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 28 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy